Pretargeting of Astatine-211 for Therapy of Metastic Prostate Cancer
Annual rept. 15 Jul 1998-14 Jul 1999
WASHINGTON UNIV SEATTLE
Pagination or Media Count:
The overall purpose of the research project is to develop a new method for treating metastatic prostate cancer. The new method being developed will selectively target the alpha particle-emitting radionuclide astatine-211 to metastatic cancer cells using the antibody-based approach termed pretargeting. The goal of the first years research effort was to optimize the reagents used, and timing for their application, in the retargeting protocol using a prostate carcinoma xenograft model LNCaP in athymic mice. This goal was largely accomplished, however, some of the results obtained in the biodistribution studies suggest that minor changes in reagents will be required. Along with the synthesis of new reagents for astatine-211 labeling, six biodistribution studies were carried out. The results indicate that very good tumor targeting was obtained, but concentrations of reagents found in liver and spleen were troublesome. Therefore, we will evaluate another antibody and possibly another prostate cancer xenograft in continuing studies. Although some changes are anticipated, the research will continue to follow the approved Statement of Work.
- Medicine and Medical Research
- Radiation and Nuclear Chemistry